Altimmune (ALT) Income towards Parent Company (2010 - 2026)
Altimmune (ALT) reported Income towards Parent Company of -$22.6 million for Q1 2026, down 15.26% year-over-year from -$26.6 million in Q1 2025, and down 138.98% on a QoQ basis from $57.9 million in Q4 2025.
Altimmune (ALT) has 17 years of Income towards Parent Company data on file, last reported at -$22.6 million in Q1 2026.
- Quarterly Income towards Parent Company fell 15.26% year-over-year to -$22.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.8 million (up 93.54% YoY) and the FY2025 annual result came in at -$2.8 million, up 97.01% from the prior year.
- Income towards Parent Company retreated to -$22.6 million in Q1 2026 per ALT's latest filing, from $57.9 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $57.9 million in Q4 2025 and bottomed at -$24.6 million in Q2 2024.
- The 5-year median for Income towards Parent Company is -$20.1 million (2022), against an average of -$11.7 million.
- The widest annual swing landed in 2022, when Income towards Parent Company soared 1049.28%; it then sank 160.71% in 2024.
- Tracing ALT's Income towards Parent Company over 5 years: stood at $51.1 million in 2022, then plunged by 117.4% to -$8.9 million in 2023, then tumbled by 160.71% to -$23.2 million in 2024, then surged by 349.74% to $57.9 million in 2025, then plunged by 138.98% to -$22.6 million in 2026.
- Per Business Quant, the three latest ALT Income towards Parent Company figures stand at -$22.6 million (Q1 2026), $57.9 million (Q4 2025), and -$19.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.56 Mn |
| Dec 31, 2025 | 57.89 Mn |
| Sep 30, 2025 | -19.01 Mn |
| Jun 30, 2025 | -22.15 Mn |
| Mar 31, 2025 | -19.58 Mn |
| Dec 31, 2024 | -23.18 Mn |
| Sep 30, 2024 | -22.85 Mn |
| Jun 30, 2024 | -24.64 Mn |
| Mar 31, 2024 | -24.39 Mn |
| Dec 31, 2023 | -8.89 Mn |
| Sep 30, 2023 | -20.67 Mn |
| Jun 30, 2023 | -16.17 Mn |
| Mar 31, 2023 | -20.09 Mn |
| Dec 31, 2022 | 51.09 Mn |
| Sep 30, 2022 | -23.52 Mn |
| Jun 30, 2022 | -20.13 Mn |
| Mar 31, 2022 | -19.54 Mn |
| Dec 31, 2021 | -5.38 Mn |
| Sep 30, 2021 | -33.51 Mn |
| Jun 30, 2021 | -24.83 Mn |
| Mar 31, 2021 | -14.86 Mn |
| Dec 31, 2020 | -10.62 Mn |
| Sep 30, 2020 | -17.77 Mn |
| Jun 30, 2020 | -16.77 Mn |
| Mar 31, 2020 | -3.89 Mn |
| Dec 31, 2019 | -4.10 Mn |
| Sep 30, 2019 | -10.94 Mn |
| Jun 30, 2019 | -3.39 Mn |
| Mar 31, 2019 | -2.10 Mn |
| Dec 31, 2018 | -30.39 Mn |
| Sep 30, 2018 | -2.35 Mn |
| Jun 30, 2018 | -9.14 Mn |
| Mar 31, 2018 | -3.17 Mn |
| Dec 31, 2017 | -18.11 Mn |
| Sep 30, 2017 | -29.91 Mn |
| Jun 30, 2017 | -3.11 Mn |
| Mar 31, 2017 | -3.58 Mn |
| Dec 31, 2016 | -3.02 Mn |
| Sep 30, 2016 | -4.81 Mn |
| Jun 30, 2016 | -1.63 Mn |
| Mar 31, 2016 | -1.23 Mn |
| Dec 31, 2015 | -1.24 Mn |
| Sep 30, 2015 | -1.32 Mn |
| Jun 30, 2015 | -2.34 Mn |
| Mar 31, 2015 | 1.46 Mn |
| Dec 31, 2014 | -2.63 Mn |
| Sep 30, 2014 | -4.63 Mn |
| Jun 30, 2014 | -439,120.00 |
| Mar 31, 2014 | -2.26 Mn |
| Dec 31, 2013 | -4.42 Mn |
| Sep 30, 2013 | -3.95 Mn |
| Jun 30, 2013 | -1.24 Mn |
| Mar 31, 2013 | -2.11 Mn |
| Dec 31, 2012 | -1.27 Mn |
| Sep 30, 2012 | -213,936.00 |
| Jun 30, 2012 | -756,543.00 |
| Mar 31, 2012 | -2.68 Mn |
| Dec 31, 2011 | 749,193.00 |
| Sep 30, 2011 | -33,496.00 |
| Jun 30, 2011 | -2.44 Mn |
| Mar 31, 2011 | -2.08 Mn |
| Dec 31, 2010 | -10.37 Mn |
| Sep 30, 2010 | -4.31 Mn |
| Jun 30, 2010 | -6.46 Mn |